Kenyan Health Patient Information Leaflet
Therapeutic agent (verify pharmacological class)
Osteoporosis, mammary carcinoma and negative nitrogen balance Clinical selection for Nandrolone decanoate should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC. Class context: Therapeutic agent (verify pharmacological class). Confirm site-specific dose, duration and monitoring before prescribing.
By deep 1.M injection]. Osteoporosis: 50mg every 3 weeks. Mammary carcinoma: 50mg every 2-3 weeks. Negative nitrogen balance: 25-50mg every 3 weeks.
Virilism; bladder irritability; breast soreness; gynaecomastia; priapism; anemia; iron deficiency; oedema; gastric irritation; hepatic dysfunction; suppression of clotting factors; prostatic carcinoma or prostatic hyperplasia; hepatic necrosis; hepatocellular carcinoma; peliosis hepatis; acne; chills; decrease or increase of libido; diarrhea; feeling of abdominal or stomach fullness; muscle cramps; trouble in sleeping; in males there is decreased sexual ability.
Store as labelled. Keep out of reach of children.